within Pharmacolibrary.Drugs.V_Various.V08C_MagneticResonanceImagingContrastMedia.V08CA02_GadotericAcid;

model GadotericAcid
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.25e-06,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.006,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0027,
    k12 = 1.1666666666666668e-06,
    k21 = 1.1666666666666668e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>GadotericAcid</td></tr><tr><td>ATC code:</td><td>V08CA02</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>6.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>4.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Gadoteric acid is a gadolinium-based contrast agent (GBCA) used in magnetic resonance imaging (MRI) to enhance the quality of images. It is mainly indicated for visualization of lesions in the brain, spine, and associated tissues in adults and children. It is currently approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after a single intravenous bolus injection.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V08CA02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end GadotericAcid;
